Last reviewed · How we verify
sevorane
At a glance
| Generic name | sevorane |
|---|---|
| Also known as | Sevoflurane |
| Sponsor | University Hospital, Ghent |
| Target | Glycine receptor subunit alpha-1, Potassium channel subfamily K member 10, Potassium channel subfamily K member 18 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
- General anesthesia
Common side effects
Key clinical trials
- Effect of Different Concentrations of Sevoflurane for Anesthesia Induction in Pediatric Ophthalmic Surgery (NA)
- General Anesthesia With and Without Muscle Relaxation and Muscle Strength Recovery (PHASE4)
- A Study Comparing Sevoflurane and Propofol in Patients Undergoing Endobronchial Ultrasound Guided Needle Aspiration
- Sedation or General Anesthesia During TAVR (NA)
- A Study to Compare the Long-term Outcomes After Two Different Anaesthetics (PHASE3)
- Topical Sevoflurane for Treatment of Chronic Leg Ulcers (PHASE4)
- An Evaluation of Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision (PHASE2)
- Effects of Anesthetics and Surgery on Sleep Quality in Patients Undergoing Posterior Spinal Instrumentation Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sevorane CI brief — competitive landscape report
- sevorane updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI